tirzepatide and glp 1 Beyond glycemia: Comparing to GLP-1 analogues | Reviews in Endocrine Metabolic Disorders Tirzepatide (GLP-1 / GIP)

Discussion Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss at 68 weeks, accompanied by significantly greater improvements in several cardiometabolic risk factors

"Food Noise": Source - LIV Body's lander and category marketing language

Before starting compounded GLP-1 medication: Verify the compounding pharmacy is properly licensed in its state Confirm the pharmacy's credentials with the prescriber Ask whether the compounded product uses semaglutide base, what excipients are used, and what testing and sterility standards apply Discuss specific risks of compounded products with the prescribing clinician Understand you are using a product with different regulatory oversight than FDA-approved alternatives Who Should Not Take GLP-1 Medications Based on prescribing guidelines, contraindications include: Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 Known hypersensitivity to the medication Current pregnancy or breastfeeding Other conditions may require careful evaluation rather than being absolute disqualifiers

Knowledge and use of breast self-examination and mammogram among women of reproductive age in Oyo State Secretariat, Ibadan, Oyo State, Nigeria

This is especially important when working with higher concentration vials where even half a unit represents a meaningful amount of medication

People have said likely it was the weight loss but I believed it was the GLP-1